MRTX Overview
Upcoming Projects (MRTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MRTX)
-
Delving into the phase 2 KRYSTAL-7 clinical trial results of adagrasib with pembrolizumab as a treatment for non-small cell lung cancer presented at ESMO 2023
Ticker: MRTX
Executed On: Oct 25, 2023 at 11:00 AM EDT -
A discussion of the KRAS G12C NSCLC landscape, including commercial assets and the AACR data updates from GDC-6036, LY3537982, and IBI351.
Tickers: AMGN, MRTX
Executed On: May 26, 2023 at 02:00 PM EDT -
Examining the potential of Eli Lillys' KRAS G12C inhibitor, LY3537982, in KRAS G12C–mutant advanced solid tumors with a focus on the Phase 1 LOXO-RAS-20001 study presented at AACR 2023
Tickers: LLY, AMGN, MRTX
Executed On: Apr 25, 2023 at 04:30 PM EDT -
Discussing Mirati's KRAS drug, Krazati (adagrasib) in treating non-small cell lung cancer post FDA approval
Ticker: MRTX
Executed On: Mar 03, 2023 at 11:30 AM EST -
A Second Look at Adagrasib (MRTX849) as a therapy for KRASG12C-mutated NSCLC
Ticker: MRTX
Executed On: Sep 29, 2022 at 07:00 PM EDT -
A First Look at Adagrasib (MRTX849) as a therapy for KRASG12C-mutated NSCLC
Ticker: MRTX
Executed On: Sep 16, 2022 at 10:30 AM EDT
Upcoming & Overdue Catalysts (MRTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (MRTX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
